COMP <GO>
PACS vs MRK // 10Y YIELD & FRED MACRO BETA
PACS Group Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: PACS 5
— MRK 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: PACS
LAST: $47.81 (-3.76%) • MKT CAP: $7.87B
macro-sensitivity
0.95
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
macro-sensitivity
0.92
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PACS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PACS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.60% | 20.70% | +3.90 | PACS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.5x | 15.3x | +0.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.11% | 3.42% | -1.31 | MRK | /fcf-yield <GO> |
| Operating Margin | 5.90% | 34.30% | -28.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 3.60% | 28.10% | -24.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 29.40% | 1.30% | +28.10 | PACS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 5.19 | -2.95 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | PACS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.6 | 56.9 | +0.79 | PACS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.95 | 0.92 | +0.03 | PACS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.5x | 18.4x | +16.10 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.87B | $361.02B | -$353.16B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PACS REV | MRK REV | PACS GROSS % | MRK GROSS % | PACS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.29B | $65.01B | 44.0% | 74.8% | $166.3M | $12.36B |
| FY 2024 | $4.09B | $64.17B | 44.0% | 76.3% | $183.4M | $18.10B |
| FY 2023 | $3.11B | $60.12B | 44.0% | 44.0% | -$76.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PACS // BETA 0.95
MRK // BETA 0.92